Prothena Corporation plc’s recently made public that its 10% Owner EcoR1 Capital, LLC unloaded Company’s shares for reported $27.74 million on May 02 ’25. In the deal valued at $8.36 per share,3,317,938 shares were sold. As a result of this transaction, EcoR1 Capital, LLC now holds 8,266,342 shares worth roughly $61.17 million.
Then, EcoR1 Capital, LLC sold 1,984,053 shares, generating $15,164,712 in total proceeds. Upon selling the shares at $7.64, the 10% Owner now owns 5,304,596 shares.
Before that, EcoR1 Capital, LLC sold 977,693 shares. Prothena Corporation plc shares valued at $7,930,166 were divested by the 10% Owner at a price of $8.11 per share. As a result of the transaction, EcoR1 Capital, LLC now holds 7,288,649 shares, worth roughly $53.94 million.
Chardan Capital Markets initiated its Prothena Corporation plc [PRTA] rating to a Buy in a research note published on December 20, 2024; the price target was $40. A number of analysts have revised their coverage, including BofA Securities’s analysts, who decreased its forecast for the stock in late January from “a Buy” to “a Neutral”. Deutsche Bank began covering PRTA with “Buy” recommendation on December 12, 2023. SVB Securities started covering the stock on April 24, 2023. It rated PRTA as “an Outperform”.
Price Performance Review of PRTA
On Monday, Prothena Corporation plc [NASDAQ:PRTA] saw its stock jump 3.06% to $7.40. Over the last five days, the stock has lost -2.76%. Prothena Corporation plc shares have fallen nearly -46.57% since the year began. Nevertheless, the stocks have fallen -66.95% over the past one year.
How much short interest is there in Prothena Corporation plc?
A steep rise in short interest was recorded in Prothena Corporation plc stocks on 2025-04-30, dropping by -0.93 million shares to a total of 7.45 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-31 was 8.38 million shares. There was a decline of -12.48%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on January 27, 2023 when Piper Sandler began covering the stock and recommended ‘”an Overweight”‘ rating along with a $94 price target.
